Browse the evidence

Omega-3 PUFA supplementation does not reduce the risk of stroke (ischemic or hemorrhagic) in primary or secondary prevention settings.

Taking fish oil supplements will not prevent you from having a stroke, whether you have had one before or not. Do not take them for stroke prevention.

GIP promotes triglyceride storage in white adipose tissue and may contribute to ectopic fat accumulation (fatty liver) in mice, acting as an obesogenic hormone in this context.

Endogenous GIP promotes fat storage in adipose tissue, particularly with high-sugar/high-fat diets. This 'obesogenic' effect is part of the biological puzzle that dual GIP/GLP-1 drugs must navigate to achieve net weight loss.

High-fat diets (HFD) induce insulin resistance in rodents primarily through the accumulation of diacylglycerol (DAG) and ceramides, which inhibit insulin signaling via PKC and PP2A activation respectively.

This explains why high-fat diets can lead to metabolic issues at a cellular level: excess fat storage in organs like the liver and muscle triggers specific molecules (DAG and ceramides) that block insulin's ability to signal for glucose uptake.

Bariatric surgery does NOT significantly reduce the incidence of esophageal, gastric, thyroid, kidney, prostate cancers, or multiple myeloma compared to conventional treatment.

While bariatric surgery reduces many obesity-related cancers, it does not appear to significantly lower the risk of esophageal, gastric, thyroid, kidney, prostate cancers, or multiple myeloma.

Racial and ethnic minorities, particularly Black and American Indian/Alaskan Native individuals, have significantly lower initiation rates of newer diabetes medications (GLP-1RAs, DPP-4Is, SGLT-2Is) compared to White individuals, independent of socioeconomic factors.

If you are a minority patient with type 2 diabetes, you may face systemic barriers to accessing newer, highly effective medications like GLP-1s or SGLT-2 inhibitors, even if you have insurance. These drugs offer significant cardiovascular and kidney benefits. It is crucial to discuss these options with your provider, understand your insurance formulary, and advocate for yourself, as disparities in initiation are well-documented and often driven by systemic factors rather than medical necessity.

Brainstem cholecystokinin-expressing (CCKAP/NTS) neurons are necessary for GLP-1 receptor agonists to induce conditioned taste avoidance (nausea/aversive effects).

The nausea and aversion caused by GLP-1 medications are mediated by specific brainstem neurons (CCKAP/NTS). Blocking these neurons prevents the aversive response, confirming that nausea is a central brain effect, not just a stomach issue. This knowledge helps in managing expectations and potentially developing strategies to reduce nausea.

Genetic disruption of AMPK-glycogen binding in skeletal muscle (via AMPK beta2 subunit mutation) leads to increased adiposity and impaired glucose handling, whereas disruption in liver (via AMPK beta1 subunit mutation) primarily increases hepatic fat deposition without affecting whole-body glucose handling.

This research highlights that the body's energy sensors (AMPK) rely on glycogen stores for stability. Disrupting this link impairs metabolic health. While this is a genetic model, it suggests that maintaining healthy glycogen stores through balanced carbohydrate intake and regular physical activity is crucial for optimal metabolic function and preventing ectopic fat accumulation.

Adherence to dipeptidyl peptidase-4 (DPP4) inhibitor therapy has no significant association with weight change in patients with type 2 diabetes.

If you are prescribed a DPP4 inhibitor for type 2 diabetes, note that adherence does not significantly affect your weight. These medications are weight-neutral, so focus on other aspects of your treatment plan for weight management.

Traditional nontargeted weight management strategies (lifestyle changes, anti-obesity medications, and metabolic/bariatric surgery) are frequently inadequate for patients with highly penetrant monogenic or syndromic obesity caused by rare genetic variants in the melanocortin-4 receptor (MC4R) pathway.

If you have severe, early-onset obesity and insatiable hunger (hyperphagia) that persists despite strict dieting or surgery, standard approaches may not work because of a genetic disruption in your brain's hunger signals. You should seek genetic testing and specialized care to access targeted therapies (like setmelanotide) that address the root hormonal cause rather than just calories.

Engineered E. coli Nissle strains (SYNB1618 and SYNB1934) expressing phenylalanine-degrading enzymes successfully reduce fasting plasma phenylalanine levels in patients with Phenylketonuria (PKU) in Phase 1/2a and Phase 2 trials.

For PKU patients, engineered bacteria are showing promise in clinical trials to lower blood phenylalanine levels. This could eventually offer more dietary flexibility, but these treatments are not yet widely available.

Genetically proxied activation of the glucagon-like peptide-1 receptor (GLP1RA) is causally associated with a reduced risk of schizophrenia.

This study suggests that medications activating the GLP-1 receptor (like semaglutide or liraglutide) may lower the risk of developing schizophrenia, primarily through their effect on body weight. For individuals at high risk of schizophrenia who are overweight, using these medications for weight management might offer a dual benefit of metabolic health and reduced psychiatric risk. However, this is based on genetic data, not direct clinical trials, so it should not replace standard psychiatric care.

Non-sulfated CCK peptides stimulate gastric acid secretion via CCK2 receptors, acting similarly to gastrin, whereas sulfated CCK inhibits acid secretion via CCK1 receptors.

The form of CCK matters. In rare tumors (CCKoma), non-sulfated CCK can cause ulcers by stimulating acid. In healthy individuals, sulfated CCK inhibits acid. This distinction is crucial for understanding gastric pathologies.

Higher genetically predicted BMI does not increase the risk of cancer mortality.

While higher BMI increases risks for other causes of death, this study did not find a link to cancer mortality.

Twelve weeks of dapiglutide (4 mg or 6 mg) once weekly does not produce a statistically significant reduction in body weight compared to placebo in adults with obesity.

In this study, taking 4 mg or 6 mg of dapiglutide once weekly for 12 weeks did not lead to significant weight loss compared to a placebo in people with obesity. The drug was safe, but the dose might be too low or the treatment period too short to see results. Future studies may need higher doses or longer durations.

Emergency department exposures to GLP-1 and GLP-1/GIP receptor agonists predominantly result in mild, self-limiting gastrointestinal symptoms (nausea, vomiting) that typically resolve within 8 to 24 hours with supportive care.

If you or someone else takes too much of a GLP-1 medication (like Ozempic or Wegovy), expect nausea and vomiting. These symptoms are usually mild and go away within a day. Focus on hydration and rest. Seek medical help if you feel faint, have severe abdominal pain, or cannot keep fluids down.

Tele-based health coaching for patients with Type 2 Diabetes (T2D) or Coronary Artery Disease (CAD) does not produce a statistically significant reduction in total healthcare and long-term care costs over an 8-year follow-up period compared to usual care.

For healthcare administrators and policymakers, this study indicates that tele-based health coaching for T2D and CAD patients should not be implemented primarily as a cost-saving measure over an 8-year horizon, as it does not significantly reduce total healthcare and long-term care costs compared to usual care. Decision-makers should focus on clinical outcomes and patient empowerment rather than expected financial savings when evaluating this intervention.

A 12-week theory-based diabetes self-management education program (BGI) provides no significant long-term benefit for cardiovascular risk factors, self-management behaviors, or quality of life in patients with Type 2 diabetes who already have well-controlled biomedical markers.

If you already have well-controlled Type 2 diabetes (normal HbA1c, blood pressure, and cholesterol), a standard 12-week self-management education program is unlikely to further improve your health numbers or quality of life compared to your regular doctor visits. Focus on maintaining your current successful routine rather than seeking additional structured education programs.

YouTube videos on semaglutide (Ozempic/Wegovy) largely fail to adequately communicate critical safety risks, specifically the risk of aspiration during anesthesia, the persistence of side effects due to the drug's long half-life, the risk of counterfeit drugs, and the lack of long-term data.

Do not rely on YouTube videos for safety information about semaglutide. They often miss critical risks like aspiration during surgery, the persistence of side effects due to the drug's long half-life, and the danger of counterfeit products. Always consult a physician for personalized advice and safety monitoring.

In people with suppressed HIV and metabolic dysfunction-associated fatty liver disease (MAFLD), adjunctive treatment with maraviroc, metformin, or their combination for 48 weeks does not significantly reduce liver fat fraction compared to antiretroviral therapy alone.

If you have HIV and fatty liver, adding maraviroc or metformin to your standard HIV treatment is unlikely to reduce the fat in your liver. The trial showed no significant benefit for liver fat reduction compared to just staying on your HIV medication. Focus on proven lifestyle strategies for metabolic health.

Childhood adversities are associated with an increased risk of fatal or non-fatal CHD events in adulthood.

Early life trauma has long-lasting physical consequences, increasing the risk of heart disease later in life. While you cannot change your childhood, being aware of this risk factor allows for more proactive cardiovascular monitoring and stress management in adulthood.

Semaglutide 0.4 mg does not significantly improve liver fibrosis stage compared to placebo in patients with NASH and fibrosis stage F2 or F3.

For patients with NASH and fibrosis stages F2 or F3, treatment with 0.4 mg of subcutaneous semaglutide daily for 72 weeks does not significantly improve liver fibrosis stage compared to placebo, despite improving NASH resolution. This suggests that while semaglutide is effective for resolving NASH, it may not be sufficient for reversing fibrosis in all patients.

Mitochondrial dysfunction, specifically the loss of mild depolarization in short-lived mice, contributes to aging by increasing ROS-mediated protein damage.

Maintaining mitochondrial health through exercise and healthy metabolism may preserve the 'mild depolarization' state seen in long-lived species, potentially reducing oxidative stress.

There is no significant association between sedentary behavior and cancer mortality.

Current evidence does not show a clear link between how much you sit and your risk of dying from cancer, unlike heart disease or diabetes.

Genetic or pharmacological ablation of senescent cells extends life span and improves health span in mice by reducing age-related pathologies.

Current research indicates that clearing out aged, non-dividing cells (senolytics) can improve health and extend lifespan in animal models. While human trials are ongoing, the mechanism suggests that targeting these specific cells could help prevent age-related diseases.